The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis
- 1 June 2009
- journal article
- review article
- Published by Wiley in Bipolar Disorders
- Vol. 11 (s2), 92-109
- https://doi.org/10.1111/j.1399-5618.2009.00714.x
Abstract
Lithium has been and continues to be the mainstay of bipolar disorder (BD) pharmacotherapy for acute mood episodes, switch prevention, prophylactic treatment, and suicide prevention. Lithium is also the definitive proof‐of‐concept agent in BD, although it has recently been studied in other psychoses as well as diverse neurodegenerative disorders. Its neurotrophic effects can be viewed as a unifying model to explain several integrated aspects of the pathophysiology of mood disorders and putative therapeutics for those disorders. Enhancing neuroprotection (which directly involves neurotrophic effects) is a therapeutic strategy intended to slow or halt the progression of neuronal loss, thus producing long‐term benefits by favorably influencing outcome and preventing either the onset of disease or clinical decline. The present article: (i) reviews what has been learned regarding lithium’s neurotrophic effects since Cade’s original studies with this compound; (ii) presents human data supporting the presence of cellular atrophy and death in BD as well as neurotrophic effects associated with lithium in human studies; (iii) describes key direct targets of lithium involved in these neurotrophic effects, including neurotrophins, glycogen synthase kinase 3 (GSK‐3), and mitochondrial/endoplasmic reticulum key proteins; and (iv) discusses lithium’s neurotrophic effects in models of apoptosis and excitotoxicity as well as its potential neurotrophic effects in models of neurological disorders. Taken together, the evidence reviewed here suggests that lithium’s neurotrophic effects in BD are an example of an old molecule acting as a new proof‐of‐concept agent. Continued work to decipher lithium’s molecular actions will likely lead to the development of not only improved therapeutics for BD, but to neurotrophic enhancers that could prove useful in the treatment of many other illnesses.Keywords
This publication has 150 references indexed in Scilit:
- Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse modelNeuroscience, 2008
- VEGF as a potential target for therapeutic intervention in depressionCurrent Opinion in Pharmacology, 2008
- Greater Cortical Gray Matter Density in Lithium-Treated Patients with Bipolar DisorderBiological Psychiatry, 2007
- A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorderMolecular Psychiatry, 2007
- Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2007
- Reduced CREB phosphorylation after chronic lithium treatment is associated with down-regulation of CaM kinase IV in rat hippocampusInternational Journal of Neuropsychopharmacology, 2006
- Evaluation of acute antiapoptotic effects of Li+ in neuronal cell culturesJournal of Neural Transmission, 2006
- Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cellsLife Sciences, 2006
- Lithium blocks the PKB and GSK3 dephosphorylation induced by ceramide through protein phosphatase-2ACellular Signalling, 2002
- The Mood‐Stabilizing Agents Lithium and Valproate RobustlIncrease the Levels of the Neuroprotective Protein bcl‐2 in the CNSJournal of Neurochemistry, 1999